Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Clinical Trial
Share your love
Atsena Publishes 12-Month Data on ATSN-101 for LCA1
Atsena Therapeutics announced that 12-month safety and efficacy data from its Phase I/II trial of ATSN-101, a gene therapy for Leber congenital amaurosis caused by GUCY2D mutations (LCA1), were published in The Lancet. ATSN-101 showed durable improvements in vision at…
Aviceda’ Kicks off Phase II/III SIGLEC Trial for AMD
Aviceda Therapeutics has initiated the second part of its Phase II/III SIGLEC trial for AVD-104, an ophthalmic candidate aimed at treating geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The company has dosed the first subject in this phase,…
Foundation Fighting Blindness Launches Gyrate Atrophy Study
The Foundation Fighting Blindness has launched a natural history study targeting gyrate atrophy, a rare and sight-threatening inherited retinal disease. Spearheading this initiative are esteemed researchers Dr. Mandeep S. Singh, MD, PhD, and Dr. David Valle, MD, from the Wilmer…
FDA Clears Eyenuk’s Additional Camera for DR Detection
Eyenuk has received FDA clearance to utilize the Topcon NW400 retinal camera with its EyeArt AI system for automated detection of diabetic retinopathy (DR). This clearance complements the system’s existing clearance for usage with Canon CR-2 AF and Canon CR-2…
Oxular’s OXU-001 Receives IND Acceptence
The U.S. Food and Drug Administration has approved Oxular Limited’s investigational new drug application (IND) for suprachoroidal OXU-001 for the treatment of diabetic macular edema (DME). The IND permits the OXEYE Phase 2 trial to proceed, which will assess the…
Alcon and Ivantis Lose Patent Battle to Sight Sciences.
Sight Sciences announced its success in defeating all four patent invalidity challenges that were filed against it by Alcon and Ivantis in the United States Patent and Trademark Office. Patent Infringement Litigation Over Hydrus® Microstent In September 2021, Sight Sciences…
Brim Biotech’s Clinical Trial for DED Kicks Off
BRIM Biotechnology has initiated the Phase 3 clinical trial of BRM421 for the treatment of Dry Eye Disease (DED) and enrolled the first patient in the trial. This multicenter, double-blind, randomized, vehicle-controlled trial will enroll over 700 patients with moderate…
Exclusive Interview with Dr. Stanley Windsor at Rayner
● Download RayPRO on App Store and Google Play.● Listen to Peer2Peer on Spotify, Apple Podcasts, Google Podcasts, and Youtube. Question 1: Can you provide an overview of Rayner’s PayPRO and Peer2Peer platforms?Dr. Stanley Windsor, Digital Innovation Manager: Thank you very much for…
Fenofibrate Reduces Diabetic Retinopathy Risk by 27%
In a groundbreaking development for diabetes management, the LENS trial has revealed that fenofibrate, a medication typically used to lower cholesterol, can significantly reduce the risk of diabetic retinopathy progression by 27%. These findings were presented at the American Diabetes…
Link Between Antioxidant Supplements and Late-Stage Dry AMD
In a significant development for the treatment of late-stage dry age-related macular degeneration (AMD), researchers at the National Institutes of Health (NIH) have identified that daily antioxidant supplements can potentially slow the progression of the disease, preserving central vision for…